No exosome-based hair-loss product has FDA approval. Clinical trials in the USA are investigational; some operate under IND protocols or as commercial clinical studies outside the FDA formal pathway. European trials are registered but operate as investigational medical procedures. Regulatory pathways for cosmetic/medical classification remain unsettled; approval timelines are uncertain.
Androgenetic alopecia and other hair-loss conditions result from follicle miniaturisation, stem-cell exhaustion within the dermal papilla, and inflammatory signalling that disrupts the hair growth cycle. Exosomes derived from umbilical-cord fibroblasts and mesenchymal stem cells contain growth factors (bFGF, VEGF, HGF), microRNAs (miR-29b regulating collagen cross-linking), and lipid mediators that promote angiogenesis, collagen deposition, and hair-follicle neogenesis in preclinical models. Sixteen registered clinical trials and four actively recruiting studies assess topical, intradermal, and systemic exosome formulations alongside platelet-rich plasma and conventional minoxidil or finasteride regimens.
Bin ich ein Kandidat? → · Hair Loss & Restoration: full overview → · Haarausfall und Haarwiederherstellung Kosten → · Cost →
Medizinisch geprüft vom Redaktionsteam von StemCellAtlas zusammen mit the Stem Plus medical team (physicians & scientists · GMP-certified Sofia laboratory · 25+ yrs international experience) der Partnerklinik Stem Plus (Sofia), gemäß ISSCR-, FDA- und EMA-Leitlinien. Educational information, not medical advice; figures indicative.
GMP-zertifizierte regenerative Medizin mitten in der EU — ab 3.000–8.000 €, ein Bruchteil der US- oder Deutschland-Preise. Individuelle Protokolle für internationale Patienten aus über 50 Ländern.
Kostenlose ärztliche Prüfung